Patents by Inventor John E. Leonard

John E. Leonard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210015924
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic- acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
    Type: Application
    Filed: June 1, 2020
    Publication date: January 21, 2021
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
  • Publication number: 20200198672
    Abstract: A rail flaw detector is configured for locating flaws in rails of a railroad track and for use with a vehicle travelling on the railroad track. The detector includes at least one signal applicator configured for applying ultrasonic signals to the rail and for receiving return signals; a mechanical subsystem connected to the applicator and to the vehicle and configured for maintaining the at least one signal applicator in operational position on the track. A human-machine interface is connected to the at least one signal applicator, is configured to control the detector and to monitor sensed rail condition. In one embodiment, the human-machine interface includes a schematic display of the rail being monitored and at least one touch screen control for controlling the mechanical subsystem and the at least one signal applicator.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 25, 2020
    Inventors: Paul Sanders UNDERWOOD, David William GIRAGOSIAN, Ian Wallace MCGRATH GAGE, Phillip EDWARDS, II, John E. LEONARD, Jacob EISLER, Ronald M. KEENAN, Joseph SETARO
  • Publication number: 20200085829
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.
    Type: Application
    Filed: August 19, 2019
    Publication date: March 19, 2020
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks BOYD, Christopher M. RUBINO
  • Publication number: 20190255179
    Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.
    Type: Application
    Filed: January 17, 2019
    Publication date: August 22, 2019
    Applicant: DURECT CORPORATION
    Inventors: Jeremy C. WRIGHT, Wilma TAMRAZ, John J. LEONARD, John W. GIBSON, Keith E. BRANHAM, Stefania SJOBECK, Brooks Boyd, Christopher M. RUBINO
  • Patent number: 7744877
    Abstract: Disclosed herein are methods of depleting peripheral blood B cells in a human host comprising administering to the host an immunologically active anti-CD20 antibody in an amount effective to deplete peripheral blood B cells in the host.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: June 29, 2010
    Assignee: Biogen Idec Inc.
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 7608241
    Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
    Type: Grant
    Filed: January 12, 2005
    Date of Patent: October 27, 2009
    Assignee: Rit Oncology, LLC
    Inventors: Paul Chinn, Ronald A. Morena, Michael J. LaBarre, John E. Leonard
  • Patent number: 6682734
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 27, 2004
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20030147885
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: September 11, 2002
    Publication date: August 7, 2003
    Applicant: IDEC PHARMACEUTICALS CORPORATION
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20030095963
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: May 22, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20030021781
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 17, 2001
    Publication date: January 30, 2003
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20020197255
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Application
    Filed: July 25, 2001
    Publication date: December 26, 2002
    Applicant: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Publication number: 20020102208
    Abstract: Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and are designed to achieve a high level of antibody radiolabeling and product stability with results which are highly reproducible.
    Type: Application
    Filed: March 1, 1999
    Publication date: August 1, 2002
    Inventors: PAUL CHINN, RONALD MORENA, MICHAEL LABARRE, JOHN E. LEONARD
  • Patent number: 5843439
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 1, 1998
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 5776456
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 7, 1998
    Assignee: IDEC Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 5736137
    Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
    Type: Grant
    Filed: November 3, 1993
    Date of Patent: April 7, 1998
    Assignee: Idec Pharmaceuticals Corporation
    Inventors: Darrell R. Anderson, Nabil Hanna, John E. Leonard, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
  • Patent number: 4913793
    Abstract: A reference electrode, optionally in combination with a measuring electrode to form a combination electrode, is disclosed in which the salt bridge comprises anionic and cationic ion exchange polymer. This polymer may be a diaphragm forming the liquid junction structure of the reference electrode. Polymer is preferably a mixture of anionic and cationic ion exchange polymer which may be either water insoluble or water soluble and is preferably converted to a form which binds equitransferent ions. When the polymer is substantially insoluble, a water-soluble thickener polymer may be incorporated in the polymer composition. Methods of measuring pH using the electrodes of the invention are also disclosed, particularly in high purity deionized water.
    Type: Grant
    Filed: January 6, 1986
    Date of Patent: April 3, 1990
    Assignee: Broadley-James Corporation
    Inventor: John E. Leonard
  • Patent number: 4872195
    Abstract: A device and method for remote control of a radio or television transmitting station located separate from a control studio and being capable of (i) monitoring preset conditions, (ii) activating notification channels for communication of monitored conditions (iii) responding to commands given remote from the device for initiating remedial or other appropriate actions. The method and device involve use of a microprocessor for locating at the transmitter station and for providing a plurality of input and output ports, means for storing preset conditions and comparing such conditions with status and metering data received at the input ports, and including a memory bank for storing separate action signals for initiating corrective action and for developing stored coded voice signals useful as part of voice synthesis. Alarm notification is provided by voice synthesized and transmitted over telephone lines which enable contact with the remote control device over any public telephone.
    Type: Grant
    Filed: November 13, 1986
    Date of Patent: October 3, 1989
    Assignee: Gentner Electronics Corporation
    Inventor: John E. Leonard
  • Patent number: 4752164
    Abstract: Chaser for cutting threads on a work piece, the chaser having thread cutting formations with crests and roots, one flank of each of said formations being relieved at a first angle from the region of the crest toward the root and being relieved at a greater angle in the region adjacent the root of the formation. The chasers may be provided in sets with odd numbered chasers being mirror images of the even numbered chasers.
    Type: Grant
    Filed: December 12, 1986
    Date of Patent: June 21, 1988
    Assignee: Teledyne Industries, Inc.
    Inventor: John E. Leonard, Jr.